Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now authorized for treating chronic kidney disease.
An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help lower their stroke and heart attack risk, a new study has found.
A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.
If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common and one of the most aggressive sub-types of kidney cancer.
Three months after her breakthrough surgery at NYU Langone Health, Towana Looney, the longest-living recipient of a genetically engineered pig kidney, is headed back home to Alabama.
Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, offering a new treatment option for cardiovascular protection. Sotagliflozin, a re
Over 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study. By creating the most complete and detailed genetic 'map' of kidney function to date,
Lupin has received tentative approval from the Food and Drug Administration for darunavir, cobicistat, emtricitabine, and tenofovir alafenamide tablets, 800 mg/150 mg/200 mg/10 mg, which is the generic of Janssen’s Symtuza.
Millions of Americans take proton pump inhibitors (PPIs) like Prilosec, Nexium, and Prevacid to manage acid reflux, heartburn, and gastroesophageal reflux disease (GERD).
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired
Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results
Some results have been hidden because they may be inaccessible to you
Show inaccessible results